Do you Trusto it ? "As I’ve written previously, the possibility that Entresto might increase the risk of dementia has been the single biggest overhang for the drug. The new data would appear to put that concern to rest, at least temporarily. Certainly there’s no reason to think it could prevent the drug’s launch. But the long term risk remains. Dementia was not rigorously monitored in PARADIGM. The next big study, PARAGON, includes much more rigorous neurocognitive assessments, including monitoring patients for amyloid on imaging and for cognitive decline, according to Bernstein analyst Timothy Anderson. As I wrote previously, it’s much easier to find a signal for a problem that you are specifically looking for than if you are just generally trying to monitor adverse events." Monkeys Prepare Honararia !
